UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers ...

The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the ...

Modern HIV treatment offers remarkable outcomes. This guide explores essential first steps, treatment advances, support ...

The decrease in CD4 cells during HIV infection seems to be driven by immune activation, which does not always correlate with viral load. Experienced clinicians are all too familiar with the ...

On these fronts, the situation with bird flu in California is improving since its height in December 2024 when Gov. Gavin ...

HIV-positive mothers with undetectable viral load can now safely breastfeed their infants, according to recently updated ...

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

Ibalizumab continues to demonstrate long-term efficacy and safety as part of combination antiretroviral therapy in heavily ...